KRW 124900.0
(-2.42%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 1.22 Billion KRW | -93.87% |
2022 | 20 Billion KRW | -63.67% |
2021 | 55.05 Billion KRW | -15.64% |
2020 | 65.26 Billion KRW | 36597.64% |
2019 | 177.83 Million KRW | 0.0% |
2018 | - KRW | -100.0% |
2017 | 15 Billion KRW | -75.71% |
2016 | 61.75 Billion KRW | 0.0% |
2015 | - KRW | 0.0% |
2014 | - KRW | 0.0% |
2013 | - KRW | -100.0% |
2012 | 2.09 Billion KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | - KRW | 0.0% |
2024 Q2 | - KRW | 0.0% |
2023 Q4 | 1.22 Billion KRW | -75.48% |
2023 FY | 1.22 Billion KRW | -93.87% |
2023 Q1 | 15 Billion KRW | -25.0% |
2023 Q2 | 10 Billion KRW | -33.33% |
2023 Q3 | 5 Billion KRW | -50.0% |
2022 FY | 20 Billion KRW | -63.67% |
2022 Q2 | 20 Billion KRW | -63.94% |
2022 Q1 | 55.46 Billion KRW | 0.73% |
2022 Q4 | 20 Billion KRW | 60.0% |
2022 Q3 | 12.5 Billion KRW | -37.5% |
2021 Q3 | 54.75 Billion KRW | 1.16% |
2021 Q4 | 55.05 Billion KRW | 0.54% |
2021 Q2 | 54.12 Billion KRW | 0.83% |
2021 Q1 | 53.68 Billion KRW | -18.13% |
2021 FY | 55.05 Billion KRW | -15.64% |
2020 Q4 | 65.57 Billion KRW | 44.91% |
2020 FY | 65.26 Billion KRW | 36597.64% |
2020 Q3 | 45.25 Billion KRW | 13.29% |
2020 Q2 | 39.94 Billion KRW | 215.51% |
2020 Q1 | 12.65 Billion KRW | 2205.05% |
2019 Q1 | 619.31 Million KRW | 0.0% |
2019 Q2 | 706.91 Million KRW | 14.15% |
2019 Q3 | 320.18 Million KRW | -54.71% |
2019 Q4 | 549.19 Million KRW | 71.53% |
2019 FY | 177.83 Million KRW | 0.0% |
2018 FY | - KRW | -100.0% |
2018 Q4 | - KRW | 0.0% |
2018 Q3 | - KRW | 0.0% |
2018 Q2 | - KRW | -100.0% |
2018 Q1 | 10 Billion KRW | -33.33% |
2017 Q2 | 45.51 Billion KRW | -9.14% |
2017 Q1 | 50.08 Billion KRW | -18.89% |
2017 FY | 15 Billion KRW | -75.71% |
2017 Q4 | 15 Billion KRW | -25.0% |
2017 Q3 | 20 Billion KRW | -56.06% |
2016 Q3 | 59.73 Billion KRW | 0.0% |
2016 Q1 | - KRW | 0.0% |
2016 FY | 61.75 Billion KRW | 0.0% |
2016 Q2 | - KRW | 0.0% |
2016 Q4 | 61.75 Billion KRW | 3.38% |
2015 FY | - KRW | 0.0% |
2015 Q4 | - KRW | -100.0% |
2015 Q3 | 8.93 Billion KRW | 6.38% |
2015 Q2 | 8.39 Billion KRW | 0.0% |
2015 Q1 | - KRW | 0.0% |
2014 Q1 | - KRW | 0.0% |
2014 Q3 | - KRW | 0.0% |
2014 Q4 | - KRW | 0.0% |
2014 FY | - KRW | 0.0% |
2014 Q2 | - KRW | 0.0% |
2013 Q3 | - KRW | -100.0% |
2013 Q1 | 2.13 Billion KRW | 2.0% |
2013 FY | - KRW | -100.0% |
2013 Q2 | 1.17 Billion KRW | -45.06% |
2013 Q4 | - KRW | 0.0% |
2012 FY | 2.09 Billion KRW | 0.0% |
2012 Q4 | 2.09 Billion KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
HLB Co., Ltd. | 17.93 Billion KRW | 93.164% |
iNtRON Biotechnology, Inc. | 258.29 Million KRW | -374.59% |
BINEX Co., Ltd. | 5.57 Billion KRW | 78.025% |
Bioneer Corporation | 12.5 Billion KRW | 90.193% |
Anterogen.Co.,Ltd. | - KRW | -Infinity% |
MEDIPOST Co., Ltd. | 6.99 Billion KRW | 82.475% |
CrystalGenomics, Inc. | 29.88 Billion USD | 95.899% |
Helixmith Co., Ltd | 151.68 Million KRW | -708.176% |
Chabiotech Co.,Ltd. | 95.06 Billion KRW | 98.711% |
Peptron, Inc. | 4.5 Billion KRW | 72.759% |
Amicogen, Inc. | 70.65 Billion KRW | 98.265% |
Genexine, Inc. | 22.68 Billion KRW | 94.595% |
HLB Therapeutics Co.,Ltd. | 1.84 Billion KRW | 33.385% |
LegoChem Biosciences, Inc. | 528.37 Million KRW | -132.003% |
ALTEOGEN Inc. | 1.24 Billion KRW | 1.874% |
PharmaResearch Co., Ltd. | 970.71 Million KRW | -26.282% |
SillaJen, Inc. | 8.13 Billion KRW | 84.933% |
JETEMA, Co., Ltd. | 60 Billion KRW | 97.957% |
OliX Pharmaceuticals,Inc | 35.36 Billion KRW | 96.533% |
Genomictree Inc. | 97.51 Million KRW | -1157.072% |
MedPacto, Inc. | 1.68 Billion KRW | 27.334% |
D&D Pharmatech | 5.12 Billion KRW | 76.061% |
EASY BIO,Inc. | 30 Billion KRW | 95.914% |
GI Innovation, Inc. | 2.9 Billion KRW | 57.788% |